I. MODIFIED AGREEMENTS
 
Biotech Co.* (Country; Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date)
JUNE
 
Prosensa BV* (the Netherlands) GlaxoSmithKline plc (UK) Initiated two further programs under their alliance covering RNA-based treatments for Duchenne's muscular dystrophy GSK made two initiation payments to Prosensa, which is now eligible for  further pre-option milestone payments based on research progress (6/24)
 
II. TERMINATED AGREEMENTS
 
Exelixis Inc. (EXEL) Bristol-Myers Squibb Co. Terminated deal to develop XL184, a small-molecule MET inhibitor Exelixis regained full rights after the firms could not agree on the scope, breadth and pace of the ongoing clinical development; BMS is paying $17M in connection with the return (6/22)
Notes:
# The information in the chart does not cover agreements between biotech companies or agricultural agreements.
The date indicated refers to the BioWorld Today issue in which the news item can be found.
* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.